本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 股票代码：000915 股票简称：华特达因 公告编号：2025-035 山东华特达因健康股份有限公司 第十一届监事会第四次会议决议公告 经审核，监事会认为董事会编制和审议《公司 2025 年半年度报 告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 （三）备查文件 经与会监事签字并加盖监事会印章的监事会决议。 特此公告 山东华特达因健康股份有限公司监事会 2025 年 8 月 8 日 山东华特达因健康股份有限公司第十一届监事会于 2025 年 7 月 26 日以电子邮件形式发出召开第四次会议的通知，并于 2025 年 8 月 6 日在公司会议室召开会议。会议应参加监事 5 名，实际参加监事 5 名。会议由监事会主席沈宝杰先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 二、监事会会议审议情况 以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年半年 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-032 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 7 月 26 日以电子邮件形式发出召开第四次会议的通知，并于 2025 年 8 月 6 日在公司会议室召开会议。会议应参加董事 8 名，实际参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 二、董事会会议审议情况 1.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年半年度报告》。 《公司 2025 年半年度报告》已经公司第十一届董事会审计委员 会审议通过。审计委员会认为：公司董事会编制的"2025 年半年度 报告"真实、准确、完整地反映了公司的财务状况和经营成果，同意 将报告提交公司董事会审议。 2.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年中期利润分配预案》。 公司拟定 2025 年中期利润分配预案为：以 2025 年 6 月 30 日 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Item%201.%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides essential preliminary information including the table of contents and key definitions [Company Profile and Key Financial Indicators](index=6&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's fundamental information and a summary of its key financial performance and position [Company Profile](index=6&type=section&id=I.%20Company%20Profile) This section outlines the company's fundamental details, including stock information, legal representation, and contact persons Company Basic Information | Item | Information | | :--- | :--- | | Stock Abbreviation | Huatedain | | Stock Code | 000915 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Zhu Xiaoping | [Key Accounting Data and Financial Indicators](index=6&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, the company achieved revenue of 1.17 billion yuan, a 1.39% increase, and net profit attributable to shareholders of 337 million yuan, up 1.69%; operating cash flow significantly rose by 61.44% to 675 million yuan due to increased sales receipts, while total assets and net assets attributable to shareholders slightly decreased from year-end H1 2025 Key Financial Data | Indicator | Current Period (Yuan) | Prior Period (Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Yuan) | 1,170,478,273.18 | 1,154,413,477.20 | 1.39% | | Net Profit Attributable to Shareholders (Yuan) | 337,467,373.75 | 331,871,287.24 | 1.69% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (Yuan) | 332,340,551.27 | 318,600,238.57 | 4.31% | | Net Cash Flow from Operating Activities (Yuan) | 674,608,179.59 | 417,869,236.68 | 61.44% | | Basic Earnings Per Share (Yuan/Share) | 1.44 | 1.42 | 1.41% | | Weighted Average Return on Net Assets | 10.96% | 10.81% | Increase 0.15 percentage points | | | **End of Current Period (Yuan)** | **End of Prior Year (Yuan)** | **YoY Change** | | Total Assets (Yuan) | 4,596,433,238.58 | 4,930,936,591.73 | -6.78% | | Net Assets Attributable to Shareholders (Yuan) | 2,780,455,844.63 | 2,911,651,440.88 | -4.51% | [Non-recurring Gains and Losses and Amounts](index=7&type=section&id=VI.%20Non-recurring%20Gains%20and%20Losses%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to 5.13 million yuan, primarily comprising government grants and fair value changes from financial assets held by non-financial enterprises Non-recurring Gains and Losses Items | Item | Amount (Yuan) | | :--- | :--- | | Government grants recognized in current profit or loss | 4,015,833.88 | | Gains and losses from financial assets and liabilities held by non-financial enterprises | 8,225,702.67 | | Other non-operating income and expenses | -827,564.67 | | Other gains and losses meeting the definition of non-recurring items | 8,161.73 | | Less: Income tax impact | 1,735,677.91 | | Less: Impact on minority interests (after tax) | 4,559,633.22 | | **Total** | **5,126,822.48** | [Management Discussion and Analysis](index=8&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's operations, financial performance, and future outlook [Company's Main Business](index=8&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company primarily engages in R&D, production, and sales of pediatric pharmaceuticals and health products, with core revenue and profit from its subsidiary Dayin Pharmaceutical, which contributed 98.59% of total revenue in H1; despite industry pressures and declining birth rates, the company benefits from national pro-child health policies, maintains a strong market position with its flagship product 'Yikexin,' expands its nutrition product line, and drives growth through integrated online-offline marketing - The company's main business is pediatric pharmaceutical and health products, with core subsidiary Dayin Pharmaceutical contributing **98.59%** of H1 operating revenue, totaling **1.15 billion yuan**[27](index=27&type=chunk) - At the industry level, pharmaceutical manufacturing faces downstream sales pressure, but national policies encouraging childbirth and child health present development opportunities for the pediatric pharmaceutical sector[25](index=25&type=chunk)[26](index=26&type=chunk) - The company has established a comprehensive product matrix covering pharmaceuticals and nutritional health products, with its flagship product 'Yikexin' holding a leading market share, while also expanding into nutritional health products like DHA and probiotics[27](index=27&type=chunk)[28](index=28&type=chunk) - The company employs a core marketing strategy of 'expert authoritative recommendation, convenient channel purchase, and professional category education,' building an integrated online and offline sales network[33](index=33&type=chunk) [Analysis of Core Competencies](index=12&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies are five-fold: professional expertise from long-term dedication to child health; strong R&D capabilities with a national enterprise technology center and pediatric drug research institute; significant brand advantage from its flagship product 'Yikexin'; product advantages of precision, safety, and palatability under a 'tailor-made' philosophy; and enhanced production efficiency through digitalization and intelligence - The company's core competencies include: - **Professional Advantage**: Long-term focus on child health, establishing an industry-leading position - **R&D Advantage**: Possesses national enterprise technology centers and pediatric drug research institutes, undertaking multiple national-level projects and securing **72** national patents - **Brand Advantage**: Flagship product 'Yikexin' has a brand value of **4.98 billion yuan**, with the company's overall brand value reaching **23.13 billion yuan** - **Product Advantage**: 'Tailor-made' philosophy ensures products precisely meet children's needs in formulation, dosage form, and taste - **Production Advantage**: Operates multiple dosage form production lines with a stringent quality management system, enhancing efficiency through digitalization[37](index=37&type=chunk)[38](index=38&type=chunk)[39](index=39&type=chunk)[40](index=40&type=chunk)[41](index=41&type=chunk)[42](index=42&type=chunk) [Analysis of Main Business Operations](index=13&type=section&id=III.%20Analysis%20of%20Main%20Business%20Operations) During the reporting period, the company's operating revenue and cost slightly increased, while administrative expenses and R&D investment decreased year-on-year; net cash flow from operating activities grew strongly by 61.44% due to increased sales collections; the pharmaceutical business, as the core, accounted for 98.59% of revenue with a stable gross margin of 85.97% Key Financial Data Year-on-Year Changes | Item | Current Period (Yuan) | Prior Period (Yuan) | YoY Change | Main Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,170,478,273.18 | 1,154,413,477.20 | 1.39% | - | | Administrative Expenses | 32,655,349.50 | 42,245,770.42 | -22.70% | - | | R&D Investment | 37,670,527.52 | 49,054,395.48 | -23.21% | - | | Net Cash Flow from Operating Activities | 674,608,179.59 | 417,869,236.68 | 61.44% | Due to increased cash received from sales of goods and services in the current period | Operating Revenue by Industry Segment | Industry | Operating Revenue (Yuan) | % of Total Revenue | Gross Margin | YoY Change | | :--- | :--- | :--- | :--- | :--- | | Pharmaceutical | 1,153,990,176.91 | 98.59% | 85.97% | 1.57% | | Other | 16,488,096.27 | 1.41% | - | -9.84% | [Analysis of Assets and Liabilities](index=14&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) As of the end of the reporting period, total assets were 4.60 billion yuan, a 6.78% decrease from year-end; asset structure remained stable with cash and equivalents accounting for 45.06% of total assets; no significant changes in liabilities; 24.74 million yuan in cash was frozen due to deposits and legal disputes, restricting its rights Changes in Major Asset Components | Asset Item | Period-end Amount (Yuan) | % of Total Assets | Change from Prior Year-end | | :--- | :--- | :--- | :--- | | Cash and Equivalents | 2,071,365,381.51 | 45.06% | 2.09% | | Fixed Assets | 826,586,254.98 | 17.98% | 0.66% | | Financial Assets Held for Trading | 697,599,794.52 | - | - | - As of the end of the reporting period, **24.74 million yuan** in cash and equivalents was frozen due to guarantee deposits and legal disputes, resulting in restricted asset rights[53](index=53&type=chunk) [Analysis of Major Holding and Participating Companies](index=16&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company's primary source of profit is its controlled subsidiary, Shandong Dayin Marine Biotechnology Co., Ltd.; during the reporting period, Dayin Pharmaceutical achieved operating revenue of 1.14 billion yuan and net profit of 633 million yuan, serving as the core support for the company's performance Shandong Dayin Marine Biotechnology Co., Ltd. Key Financial Data | Indicator | Amount (Yuan) | | :--- | :--- | | Total Assets | 3,069,883,120.55 | | Net Assets | 2,636,850,885.09 | | Operating Revenue | 1,135,917,144.76 | | Operating Profit | 737,506,983.20 | | Net Profit | 633,104,950.93 | [Risks and Countermeasures](index=17&type=section&id=X.%20Risks%20and%20Countermeasures) The company faces two main risks: market challenges from downstream sales pressure and declining birth rates, and potential risks in managing and disposing of non-core businesses and assets (e.g., Huate Zhixin Materials, Wolong School) that may not meet expectations; the company plans to address market challenges by deepening market penetration, diversifying product lines, and strengthening online marketing, while actively promoting compliant handling of non-core assets - **Market Risk**: Downstream sales pressure in the pharmaceutical industry and declining birth rates adversely impact demand for infant and child nutrition and health products[63](index=63&type=chunk) - **Countermeasures**: Enhance the penetration rate of the core product 'Yikexin,' strengthen marketing for key products, and vigorously develop online channels to precisely meet customer needs[63](index=63&type=chunk) - **Management Risk**: The liquidation of non-core business (Huate Zhixin Materials) and resolution of asset occupation issues (Wolong School) may face risks of not progressing as expected[64](index=64&type=chunk) - **Countermeasures**: Continuously focus on the core pediatric pharmaceutical and health business, formulate detailed plans to actively promote the disposal of non-core businesses and assets, and protect company interests[64](index=64&type=chunk) [Corporate Governance, Environment, and Society](index=17&type=section&id=Item%204.%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section details the company's governance structure, environmental initiatives, and social responsibility efforts [Profit Distribution Plan](index=18&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20in%20the%20Current%20Period) The Board of Directors approved the H1 2025 profit distribution plan, proposing a cash dividend of 5 yuan (tax inclusive) per 10 shares to all shareholders based on the total share capital as of June 30, 2025, with no bonus shares or capital reserve conversions; this proposal awaits shareholder approval H1 2025 Profit Distribution Proposal | Item | Content | | :--- | :--- | | Dividend per 10 shares (Yuan) (tax inclusive) | 5 | | Bonus shares per 10 shares (shares) | 0 | | Share capital base for distribution proposal (shares) | 234,331,485 | | Cash dividend amount (Yuan) (tax inclusive) | 117,165,742.50 | [Social Responsibility](index=18&type=section&id=V.%20Social%20Responsibility) The company actively fulfills its social responsibilities through its subsidiary Dayin Pharmaceutical, focusing on child health; key initiatives include: disseminating scientific parenting knowledge via multimedia platforms; promoting the improvement of pediatric drug policies and standards; establishing the 'Dayin Love Fund' to aid children in need; and conducting various charitable activities such as donating medicines and supporting rural education, comprehensively safeguarding children's healthy growth - Continuously disseminates popular science content on child nutrition, health, and scientific medication through systematic communication matrices, including social media and self-media, in collaboration with expert organizations[73](index=73&type=chunk) - Actively assumes industry responsibility, leading the establishment of a pediatric drug professional committee to promote the promulgation of relevant policies and standards[74](index=74&type=chunk) - Actively gives back to society through the 'Dayin Love Fund' and various public welfare projects, such as donating pediatric medicines to flood-affected areas in Guizhou and building hope primary schools[75](index=75&type=chunk)[76](index=76&type=chunk) [Significant Matters](index=19&type=section&id=Item%205.%20Significant%20Matters) This section reports on key events and transactions impacting the company during the reporting period [Litigation Matters](index=20&type=section&id=VIII.%20Litigation%20Matters) The company had no significant litigation or arbitration matters during the reporting period; there was one other lawsuit involving an engineering payment dispute with former subsidiary Shandong Huate Smart Technology Co., Ltd., with an amount of 3.79 million yuan, for which Huate Smart is responsible for the related payables - The company had no significant litigation or arbitration matters during the reporting period[84](index=84&type=chunk) [Significant Related Party Transactions](index=20&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company did not engage in significant related party transactions related to daily operations, nor did it undertake other major related party transactions such as asset or equity acquisitions or disposals - The company did not engage in significant related party transactions related to daily operations during the reporting period[86](index=86&type=chunk) [Share Changes and Shareholder Information](index=22&type=section&id=Item%206.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in share capital and provides an overview of the company's shareholder structure [Shareholder Numbers and Shareholding](index=23&type=section&id=III.%20Shareholder%20Numbers%20and%20Shareholding) As of the end of the reporting period, the company had 25,635 common shareholders; the controlling shareholder is Shandong Huate Holding Group Co., Ltd., with a 22.00% stake; among the top ten shareholders, Guo Weisong is the second largest, holding 8.78% - The total number of common shareholders at the end of the reporting period was **25,635**[106](index=106&type=chunk) Top Five Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Shandong Huate Holding Group Co., Ltd. | State-owned Legal Person | 22.00% | 51,544,340 | | Guo Weisong | Domestic Natural Person | 8.78% | 20,581,124 | | Yin Juntao | Domestic Natural Person | 3.52% | 8,246,393 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Person | 3.15% | 7,389,501 | | Huitianfu Fund Management Co., Ltd. - Social Security Fund 17022 Portfolio | Other | 1.94% | 4,542,984 | [Bond-Related Information](index=25&type=section&id=Item%207.%20Bond-Related%20Information) This section provides details on any bond-related activities or outstanding bonds of the company [Bond-Related Information](index=25&type=section&id=Bond%20Related%20Information) The company had no bond-related matters during the reporting period - The company had no bond-related matters in the current reporting period[113](index=113&type=chunk) [Financial Report](index=25&type=section&id=Item%208.%20Financial%20Report) This section presents the company's comprehensive financial statements and notes, detailing its financial position and performance [Financial Statements](index=25&type=section&id=II.%20Financial%20Statements) This section includes the company's unaudited H1 2025 financial statements, comprising consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity - The company's half-year financial report is unaudited[114](index=114&type=chunk) [Significant Accounting Policies and Estimates](index=42&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section elaborates on the basis of preparation, enterprise accounting standards, and significant accounting policies and estimates followed by the company in preparing its financial statements, covering key areas such as revenue recognition, financial instruments, long-term equity investments, R&D expenditures, and government grants - Financial statements are prepared on a going concern basis, in accordance with enterprise accounting standards[146](index=146&type=chunk)[147](index=147&type=chunk) - Revenue recognition policy: Revenue is recognized when the customer obtains control of the related goods or services, primarily for pharmaceutical product sales, recognized upon customer receipt[203](index=203&type=chunk)[204](index=204&type=chunk) - R&D expenditure policy: Internal R&D projects are divided into research and development phases; research phase expenditures are expensed, while development phase expenditures are capitalized upon meeting specific conditions (e.g., technical and economic feasibility)[191](index=191&type=chunk) [Notes to Consolidated Financial Statement Items](index=57&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes and explanations for each major item in the consolidated financial statements, including the composition, changes, and specific circumstances of accounts such as cash and equivalents, accounts receivable, inventories, fixed assets, intangible assets, goodwill, accounts payable, revenue and costs, and various expenses

证券代码：000915 证券简称：华特达因 公告编号：2025-033 山东华特达因健康股份有限公司 关于公司2025年中期利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、审议程序 （一）董事会审议情况 含本次拟实施的 2025 年中期利润分配，公司本年度累计现金分 红总额为 117,165,742.50 元，占半年度公司合并报表归属于上市公司 股东净利润的比例为 34.72%。 本预案将在股东会审议通过之日起两个月内实施完毕。若在实施 前公司总股本因股权激励行权、可转债转股、股份回购等原因而发生 变化的，公司将按照"现金分红分配比例固定不变"的原则对现金分 红总额进行调整。 三、现金分红方案合理性说明 2025 年 8 月 6 日，山东华特达因健康股份有限公司（以下简称 "公司"）第十一届董事会第四次会议审议通过了《公司 2025 年中 期利润分配预案》，本事项尚需提交公司 2025 年第一次临时股东会 审议。 二、2025 年中期利润分配预案的基本情况 公司 2025 年 1-6 月合并实现营业收入 1,170,478,273.18 ...

Group 1 - The company, Shandong Huate Dain Health Co., Ltd., has signed an exclusive distribution agreement with Nobelpharma Co., Ltd. for melatonin granules (brand name: Manlejing) in mainland China [2][6] - The product is set to be approved for sale in China by July 2025 and is aimed at treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders, addressing a significant clinical need in the market [3][9] - Nobelpharma, established in 2003 and based in Tokyo, Japan, focuses on the research and production of rare disease medications and has successfully launched three products in China [4] Group 2 - The agreement grants Dain Kangjian exclusive rights for the import, marketing, and sales of the product in mainland China, excluding Hong Kong, Macau, and Taiwan [6] - The initial term of the agreement is set for 10 years, with the possibility of renewal upon mutual agreement [7] - Dain Kangjian is responsible for market promotion and channel development, while Nobelpharma must ensure product quality meets Chinese regulatory standards and provide necessary technical support [8] Group 3 - The introduction of this product fills a market gap as it is the first melatonin formulation approved in China for treating sleep issues in children with neurodevelopmental disorders, showcasing significant clinical value and market potential [9] - This partnership enhances the company's pediatric product line, reinforcing its leading position in the children's health sector [10]

Group 1 - The Ministry of Finance and the State Taxation Administration announced the resumption of VAT on interest income from newly issued government bonds, local government bonds, and financial bonds starting from August 8 [1] - The Hong Kong High Court ruled that Zong Fuli cannot withdraw or transfer any assets from the bank account of Jianhao Venture Capital Limited until the litigation results are finalized [1] - The U.S. non-farm payrolls increased by only 73,000 in July, the lowest in nine months, significantly below the expected 110,000, indicating a rapid slowdown in the labor market [1] Group 2 - The central bank emphasized the implementation of a moderately loose monetary policy and enhancing the effectiveness of monetary policy measures [2] - The National Development and Reform Commission plans to accelerate the establishment of new policy financial tools to support private enterprises in major national projects [2] - The Supreme Court issued judicial interpretations on labor disputes, clarifying that agreements not to participate in social insurance are invalid [2] Group 3 - The Ministry of Finance reported six typical cases of local government hidden debt, with Xiamen, Chengdu, and Wuhan East Lake New Technology Development Zone adding hidden debts of 68.396 billion, 61.408 billion, and 10.385 billion respectively [3] Group 4 - The A-share market experienced a decline, with the Shanghai Composite Index falling by 0.37% to 3559.95 points, and the total trading volume for the day was 1.62 trillion [4] - The Hong Kong Hang Seng Index closed down 1.07% at 24507.81 points, marking four consecutive days of decline [5] Group 5 - The Hong Kong Stock Exchange published a consultation summary on optimizing IPO pricing and public market regulations, allowing a reduction in the minimum allocation ratio for IPO book-building from 50% to 40% [5] - The Shanghai Stock Exchange clarified that pre-application consultation is not a mandatory procedure for project acceptance [5] Group 6 - In the electric vehicle sector, July delivery figures showed significant growth for several companies, with Leap Motor surpassing 50,000 deliveries for the first time [9] - The Ministry of Industry and Information Technology issued a digital transformation implementation plan for the machinery industry, aiming for 50% of enterprises to reach a maturity level of two or above by 2027 [10] Group 7 - The State Administration of Foreign Exchange outlined key tasks for foreign exchange management, emphasizing the need for macro-prudential management of cross-border capital flows [21] - The onshore RMB closed at 7.2106 against the USD, down 176 basis points from the previous trading day [21]

Group 1 - Nobelpharma's melatonin product, Manlejing®, has been approved for sale in China, specifically for improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marking it as the first melatonin formulation approved for this indication in the country [1][2] - Huate Dain has announced that its subsidiary, Dain Health, has signed an exclusive distribution agreement for Manlejing® in mainland China, with an initial term of 10 years [1][2] - The product was previously launched in Japan in 2020 and has shown significant results in reducing sleep latency in clinical trials [2] Group 2 - Other companies, such as Changchun High-tech and Eifang Pharmaceutical, have already established a presence in the market for treating sleep difficulties associated with neurodevelopmental disorders in children [3] - Huate Dain is a leading player in the children's pharmaceutical health sector in China, with its main revenue and profit sources coming from its subsidiary, Dain Pharmaceutical, which focuses on the development, production, and marketing of children's medications [3]

每经AI快讯，有投资者在投资者互动平台提问：近期二级市场行情火爆，贵公司股价却萎靡不振，坊 间传闻贵公司半年度业绩不佳，一些消息灵通的大户提前撤退，将筹码抛售给不明真相的散户。请问是 否属实？ 华特达因（000915.SZ）8月1日在投资者互动平台表示，公司2025年半年度报告定于2025年8月8日披 露，业绩情况请您以公司披露的《2025年半年度报告》为准。 （文章来源：每日经济新闻） ...

Core Viewpoint - Huate Dain (000915.SZ) has signed an exclusive distribution agreement with Nobelpharma Co., Ltd for melatonin granules (brand name: Manlejing®) in mainland China, marking a significant step in addressing the treatment gap for sleep difficulties in children with neurodevelopmental disorders [1] Group 1 - Huate Dain's subsidiary, Beijing Dain Kangjian Pharmaceutical Co., Ltd, will be the exclusive distributor for Manlejing® in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025, targeting children aged 6-15 with sleep difficulties [1] - This agreement allows Huate Dain to manage the import, marketing, and sales of the product, fulfilling a critical clinical need in the domestic market [1]

Group 1 - The company Huate Dain announced that its subsidiary Beijing Dain Kangjian has reached an agreement with Japan's Nobel Pharma Co., Ltd. for the exclusive general distribution of melatonin granules (Manlejing®) in mainland China [1] - Dain Kangjian will be the exclusive general distributor of this product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is expected to be approved for sale in China by July 2025 and is the first melatonin formulation approved for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders in the country [1]